U.S. Withdraws From WHO But Still Dependent on Flu Vaccine Network- For Now

What Happened

The United States has begun the process of withdrawing from the World Health Organization (WHO), following an executive order in January signaling its intent to leave. Despite the withdrawal, U.S. officials are still expected to participate in upcoming meetings tied to global influenza surveillance, including sessions that help determine the composition of the 2026–2027 Northern Hemisphere flu vaccine.

Each year, the World Health Organization convenes experts to review data from its Global Influenza Surveillance and Response System, a network of more than 150 laboratories in over 120 countries. The group analyzes which influenza strains are circulating and recommends which should be included in seasonal vaccines. These recommendations are typically issued in February for the Northern Hemisphere and in September for the Southern Hemisphere.

WHO guidance does not legally bind countries, but it strongly influences national health authorities and vaccine manufacturers. In the United States, the Food and Drug Administration makes the final decision on vaccine composition, generally aligning with WHO’s analysis and its own advisory committees.

WHO officials have acknowledged periodic funding and reporting challenges that can affect the flow of virus samples, though the surveillance network continues to operate. Even as the U.S. formalizes its withdrawal, cooperation on influenza monitoring appears to be continuing, at least for now.

Why It Matters

Influenza viruses mutate frequently and spread quickly across borders. Because strains often emerge in one region before spreading to others, international data sharing plays an integral role in predicting which variants are most likely to circulate months later. The WHO network compiles viral samples and genetic sequencing data from around the world, providing scientists with a far better view than any single country could assemble on its own.

Current Investors: Act By 2/26

With our breakthrough technology driving our company towards the next stage of development, we’re offering an exclusive opportunity for our current investors to reinvest at $11/share by 2/26.*

EnergyX is actively deploying its patented lithium production technology across projects in the U.S.  and Chile, supporting one of the lowest-cost production models in the world. 

With nearly 150,000 gross acres of lithium-rich resources between our two projects and the potential to support 100,000+ tonnes of annual lithium output once both projects are complete, EnergyX is positioned to emerge as a leader amongst some of the biggest names in renewable energy. 

Having already achieved its milestones, the window of opportunity is rapidly closing as EnergyX advances toward the next phase of development. This next stage marks a clear moment for existing investors to participate as the company moves out of piloting and towards commercialization.

Reinvest now at our website.

Vaccine production requires long lead times. Manufacturers typically select three or four strains, then grow them in eggs or cell-based systems, test for quality and safety, and distribute millions of doses ahead of the fall flu season. If predictions about circulating strains miss the mark, vaccine effectiveness can decline.

The 2017–2018 flu season illustrates that risk. During that year, vaccine effectiveness in the United States was estimated at about 38% overall, according to the Centers for Disease Control and Prevention. The season was associated with an estimated 61,000 U.S. deaths, making it one of the deadliest in recent years. While flu severity depends on many factors, strain mismatch can reduce the effectiveness of vaccines in preventing illness.

The U.S. withdrawal from the WHO raises practical questions about long-term access to global surveillance data and collaborative research. Should participation in international networks become more limited, American health officials may need to rely more heavily on domestic surveillance or bilateral agreements. Any disruption in data flow could complicate strain selection decisions, though it is not yet clear how significantly current cooperation will change.

How It Affects You

The effectiveness of annual flu shots is heavily dependent on how accurately scientists predict which strains will circulate during the upcoming season. Those predictions are primarily supported by global surveillance data collected months in advance. If access to this international data were reduced, it could narrow the information available when vaccine strain decisions are made.

Timing is crucial, as recommendations issued in late winter guide vaccine production for distribution in the fall. Manufacturers must commit to specific strains well before flu season begins, leaving little room for adjustment. Accurate forecasting improves the odds that the vaccine you receive will closely match circulating viruses.

For now, collaboration on influenza surveillance appears to be continuing despite the U.S.’s formal withdrawal process. The long-term structure of that relationship will shape how closely the United States remains tied to the global system that underpins seasonal flu vaccine development.

*Disclaimer: This is a paid advertisement for EnergyX's Regulation A+ Offering. Please read the offering circular at invest.energyx.com/. Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.